4.6 Article

Performance of the 10-2 and 24-2 Visual Field Tests for Detecting Central Visual Field Abnormalities in Glaucoma

期刊

AMERICAN JOURNAL OF OPHTHALMOLOGY
卷 196, 期 -, 页码 10-17

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2018.08.010

关键词

-

资金

  1. NATIONAL INSTITUTES OF HEALTH/NATIONAL EYE INSTITUTE [EY021818, EY011008, EY14267, EY027510, EY019869, P30EY022589, EY026574]
  2. Alcon
  3. Allergan
  4. Pfizer
  5. Merck
  6. Santen
  7. National Health and Medical Research Council Early Career Fellowship [1104985]
  8. NATIONAL EYE INSTITUTE [R01EY011008, R01EY019869, P30EY022589, R01EY021818, R01EY026574, U10EY014267, R01EY027510] Funding Source: NIH RePORTER

向作者/读者索取更多资源

PURPOSE: To compare the performance of the pattern standard deviation (PSD) values derived from the central 12 locations of the 24-2 visual field test (C24-2) to the entire 10-2 test for detecting central visual field abnormalities in eyes with, suspected of having, or at risk of having glaucoma. DESIGN: Cross-sectional case-control study. METHODS: Eyes with, suspected of having, or at risk of having glaucoma, based on masked grading of optic disc stereophotographs and/or ocular hypertension (intraocular pressure >= 22 mm Hg) were included as cases (n = 523). Eyes from healthy participants were included as controls (n = 107) to allow the 2 tests to be compared at matched specificities. The sensitivity to detect cases at 95% specificity using PSD values derived from the entire 10-2 test and C24-2 were compared. RESULTS: The sensitivity of the 10-2 and C24-2 PSD values was not significantly different between the 10-2 and C24-2 at matched specificities (35.9% and 35.4% respectively; P = .900). There was also a substantial agreement between the cases detected by both methods (kappa = 0.80 +/- 0.04), and a very strong association between the PSD values from the 2 methods (R-2 = 0.91). CONCLUSIONS: 10-2 and 24-2 tests identified a similar number of eyes with, suspected of having, or at risk of having glaucoma as having central visual field abnormalities using PSD values. These findings do not mean that 10-2 tests are not useful, but highlight the need for further studies to determine the potential advantages of 10-2 tests through equivalent comparisons against 24-2 tests to ensure appropriate recommendations are made about its incorporation into the glaucoma standard of care. (Am J Ophthalmol 2018;196:10-17. (C) 2018 Elsevier Inc. All rights reserved.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据